Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts

被引:217
作者
Andersen, JH [1 ]
Osbakk, SA
Vorland, LH
Traavik, T
Gutteberg, TJ
机构
[1] Univ Tromso Hosp, Dept Microbiol, N-9038 Tromso, Norway
[2] Univ Tromso, Sch Med, Inst Med Biol, Dept Med Microbiol, N-9001 Tromso, Norway
[3] Univ Tromso, Sch Med, Inst Med Biol, Dept Virol, N-9001 Tromso, Norway
关键词
human cytomegalovirus (HCMV); lactoferrin; lactoferricin;
D O I
10.1016/S0166-3542(01)00146-2
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Lactoferrin is mainly produced by polymorphonuclear leukocytes and has been demonstrated in mammalian milk and external secretions. Lactoferrin is an iron-binding, multifunctional protein and may play an important role in immune regulation and in defense mechanisms against bacteria, fungi and viruses. Lactoferricin is a potent antimicrobial peptide generated from the N-terminal part of lactoferrin by pepsin cleavage. We demonstrate that lactoferrins from different species and its N-terminal peptide lactoferricin (particularly the cyclic form) inhibit expression of early and late antigens, as well as production of infectious viral progeny during human cytomegalovirus (HCMV) infection in vitro. Iron-saturated lactoferrin did not affect HCMV antigen expression. Heparin had the same effects as iron-depleted lactoferrin. Yet, mixtures of lactoferrin and heparin did not inhibit HCMV multiplication i.e. lactoferrin and heparin seemed to mutually block each other's antiviral activities. HCMV-infected cells exposed to lactoferrin and cyclic lactoferricin contained less intracellular virus than unexposed cells. The antiviral activity of cyclic lactoferricin was more than seven-fold weaker than that of the maternal molecule. Lactoferrin and cyclic lactoferricin prevented HCMV entrance into the host cell. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 40 条
[1]
STRUCTURE OF HUMAN LACTOFERRIN - CRYSTALLOGRAPHIC STRUCTURE-ANALYSIS AND REFINEMENT AT 2.8-A RESOLUTION [J].
ANDERSON, BF ;
BAKER, HM ;
NORRIS, GE ;
RICE, DW ;
BAKER, EN .
JOURNAL OF MOLECULAR BIOLOGY, 1989, 209 (04) :711-734
[2]
BAKER EN, 1994, ADV EXP MED BIOL, V357, P1
[3]
BELLAMY W, 1993, MED MICROBIOL IMMUN, V182, P97, DOI 10.1007/BF00189377
[4]
IDENTIFICATION OF THE BACTERICIDAL DOMAIN OF LACTOFERRIN [J].
BELLAMY, W ;
TAKASE, M ;
YAMAUCHI, K ;
WAKABAYASHI, H ;
KAWASE, K ;
TOMITA, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1121 (1-2) :130-136
[5]
BRITT WJ, 1995, FIELDS VIROLOGY, P2493
[6]
QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[7]
INITIATION OF HUMAN CYTOMEGALOVIRUS-INFECTION REQUIRES INITIAL INTERACTION WITH CELL-SURFACE HEPARAN-SULFATE [J].
COMPTON, T ;
NOWLIN, DM ;
COOPER, NR .
VIROLOGY, 1993, 193 (02) :834-841
[8]
STRUCTURAL ORGANIZATION OF THE MOUSE LACTOFERRIN GENE [J].
CUNNINGHAM, GA ;
HEADON, DR ;
CONNEELY, OM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 189 (03) :1725-1731
[9]
STRUCTURE OF THE RECOMBINANT N-TERMINAL LOBE OF HUMAN LACTOFERRIN AT 2.0-ANGSTROM RESOLUTION [J].
DAY, CL ;
ANDERSON, BF ;
TWEEDIE, JW ;
BAKER, EN .
JOURNAL OF MOLECULAR BIOLOGY, 1993, 232 (04) :1084-1100
[10]
DAY CL, 1992, J BIOL CHEM, V267, P13857